NasdaqGS:TSHA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$976.8m

Last Updated

2021/06/19 23:23 UTC

Data Sources

Company Financials +

Executive Summary

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Taysha Gene Therapies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TSHA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: TSHA's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

5.1%

TSHA

-3.2%

US Biotechs

-1.9%

US Market


1 Year Return

n/a

TSHA

18.9%

US Biotechs

38.2%

US Market

Return vs Industry: Insufficient data to determine how TSHA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how TSHA performed against the US Market.


Shareholder returns

TSHAIndustryMarket
7 Day5.1%-3.2%-1.9%
30 Day18.9%2.6%1.1%
90 Day8.1%1.6%4.3%
1 Yearn/a20.6%18.9%40.4%38.2%
3 Yearn/a9.2%4.7%57.5%47.8%
5 Yearn/a60.4%47.8%127.2%101.7%

Long-Term Price Volatility Vs. Market

How volatile is Taysha Gene Therapies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Taysha Gene Therapies undervalued compared to its fair value and its price relative to the market?

4.36x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TSHA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TSHA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TSHA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: TSHA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TSHA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TSHA is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is Taysha Gene Therapies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-5.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TSHA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TSHA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TSHA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if TSHA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if TSHA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TSHA is forecast to be unprofitable in 3 years.


Past Performance

How has Taysha Gene Therapies performed over the past 5 years?

-374.0%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: TSHA is currently unprofitable.

Growing Profit Margin: TSHA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if TSHA's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare TSHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TSHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: TSHA has a negative Return on Equity (-38.86%), as it is currently unprofitable.


Financial Health

How is Taysha Gene Therapies's financial position?


Financial Position Analysis

Short Term Liabilities: TSHA's short term assets ($239.6M) exceed its short term liabilities ($19.0M).

Long Term Liabilities: TSHA's short term assets ($239.6M) exceed its long term liabilities ($999.0K).


Debt to Equity History and Analysis

Debt Level: TSHA is debt free.

Reducing Debt: TSHA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TSHA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TSHA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 137.5% each year.


Dividend

What is Taysha Gene Therapies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TSHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TSHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TSHA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TSHA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TSHA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

R. Session (41 yo)

1.75yrs

Tenure

US$4,695,252

Compensation

Mr. R. A. Session, II, is Founder, President, Chief Executive Officer and Director at Taysha Gene Therapies, Inc September 2019. Mr. Session serves as Entrepreneur-in-Residence of the University of Texas S...


CEO Compensation Analysis

Compensation vs Market: R.'s total compensation ($USD4.70M) is above average for companies of similar size in the US market ($USD2.38M).

Compensation vs Earnings: Insufficient data to compare R.'s compensation with company performance.


Leadership Team

Experienced Management: TSHA's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: TSHA's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TSHA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: TSHA only recently listed within the past 12 months.


Top Shareholders

Company Information

Taysha Gene Therapies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Taysha Gene Therapies, Inc.
  • Ticker: TSHA
  • Exchange: NasdaqGS
  • Founded: 2019
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$976.754m
  • Shares outstanding: 37.92m
  • Website: https://www.tayshagtx.com

Number of Employees


Location

  • Taysha Gene Therapies, Inc.
  • 2280 Inwood Road
  • Dallas
  • Texas
  • 75235
  • United States

Listings


Biography

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous sys...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/19 23:23
End of Day Share Price2021/06/18 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.